DURHAM, N.C., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 10:55 a.m. ET at the InterContinental New York Barclay Hotel.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at  ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. In addition, Chimerix has in early-stage development a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website,  www.chimerix.com.

CONTACT:Investor Relations: ir@chimerix.com or Will O'Connor Stern Investor Relations Will@sternir.com 212-362-1200

Media: Becky Vonsiatsky W2O Group bvonsiatsky@w2ogroup.com 413-478-2003

Primary Logo